<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23380" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Imipramine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fayez</surname>
            <given-names>Rola</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rola Fayez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23380.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Imipramine is a medication used in the treatment of depression and anxiety. It is a tertiary amine tricyclic antidepressant. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of imipramine therapy in the clinical setting as continuous monitoring of the drug and the acute management of tricyclic overdose. These factors will be clinically relevant and essential for interprofessional team members in taking care of patients on imipramine therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe common adverse effects associated with imipramine.</p></list-item><list-item><p>Explain the need for monitoring of imipramine to ensure maintaining the therapeutic level and avoid the toxic effects of imipramine.</p></list-item><list-item><p>Review the interventions for an imipramine overdose.</p></list-item><list-item><p>Summarize how collaboration and effective communication among healthcare providers can promote patient care when monitoring the dose of imipramine and prompt treatment in imipramine overdose.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23380&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23380">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23380.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Imipramine&#x000a0;is a tertiary amine tricyclic antidepressant. Tricyclic antidepressants (TCAs) had been approved by the Food and Drug Administration (FDA) as antidepressants in the 1950s. Although it is&#x000a0;FDA approved for the treatment of depression, it is a&#x000a0;second-line treatment, notably in severe&#x000a0;depression with melancholic and atypical features due to its undesirable side effects and its toxicity in overdose. Imipramine is an adjunctive therapy in nocturnal enuresis in children above six years of age. There are other off-label uses of imipramine as in the treatment of chronic neuropathic pain and panic disorder.<xref ref-type="bibr" rid="article-23380.r1">[1]</xref><xref ref-type="bibr" rid="article-23380.r2">[2]</xref><xref ref-type="bibr" rid="article-23380.r3">[3]</xref><xref ref-type="bibr" rid="article-23380.r4">[4]</xref></p>
      </sec>
      <sec id="article-23380.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Imipramine&#x000a0;blocks the reuptake of&#x000a0;norepinephrine and serotonin. Since imipramine is a tertiary amine, it has a greater affinity for serotonin, and it has more anticholinergic side effects, which can prove helpful in treating enuresis. Imipramine blocks D-2 receptors. Additionally, imipramine and other tricyclics have different effects on other receptors. It blocks antimuscarinic receptors, thus, producing anticholinergic adverse effects. It also&#x000a0;blocks alpha 1 and 2 adrenergic and H1 receptors.<xref ref-type="bibr" rid="article-23380.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-23380.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Imipramine is available both in tablets and in capsules. The tablets are available in doses of 10, 25, 50 mg, while the capsules are available in doses of 75, 100, 125, 150 mg. Due to the side effects associated with imipramine and with other tricyclic antidepressants, the recommendation is to initiate treatment at a lower dose and then titrate up gradually to higher doses. Some metal ions such as copper, zinc, and magnesium can affect the efficiency of passive and active transport of imipramine.<xref ref-type="bibr" rid="article-23380.r6">[6]</xref><xref ref-type="bibr" rid="article-23380.r7">[7]</xref></p>
      </sec>
      <sec id="article-23380.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Since imipramine acts on various receptors in the body, it&#x000a0;can cause adverse effects on some organs and systems. In the central and autonomic nervous system, the antihistaminic effects of imipramine can lead to dizziness, sedation, confusion, delirium, seizures, increased appetite, and weight gain.</p>
        <p>The anticholinergic properties of imipramine can produce undesired side effects such as blurred vision, constipation, tachycardia, confusion, dry mouth, urinary retention, delirium, and narrow-angle glaucoma. Therefore, it is crucial to use imipramine cautiously in patients with acute angle glaucoma, paralytic ileus, urinary retention, and benign prostatic hypertrophy. The cardiovascular side effects include cardiac arrhythmia, which is the leading cause of death in tricyclic antidepressant overdose. Other adverse effects include GI upset, mild elevation of liver enzymes,&#x000a0;sexual dysfunction, and diaphoresis. TCAs may rarely cause bone marrow suppression. Diaphoresis and orthostatic hypotension are mainly caused by noradrenergic receptor manipulation, while sexual dysfunction is due to&#x000a0;serotonergic effects such as impaired arousal and orgasms.</p>
        <p>Serotonin syndrome is a life-threatening condition, and it occurs with concurrent use of other serotonergic drugs as SSRI, triptans, tramadol, lithium, St John's wort, and tryptophan. Patients will present with altered mental state, autonomic changes as tachycardia, and neuromuscular changes as tremor, rigidity, and myoclonus. Imipramine can worsen suicidal ideation during the initial period of taking this medication in patients under the age of 24. Imipramine and other antidepressants can lead to the precipitation of a manic or mixed episode in a bipolar patient.<xref ref-type="bibr" rid="article-23380.r7">[7]</xref><xref ref-type="bibr" rid="article-23380.r8">[8]</xref>&#x000a0;Therefore, it is essential to obtain pertinent history to rule out bipolar disorder in patients with a history of depression before prescribing imipramine.</p>
      </sec>
      <sec id="article-23380.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Imipramine is contraindicated in hypersensitivity to the drug, especially in cross-reactivity with other dibenzodiazepines, in acute recovery from myocardial infarction, and when used concurrently with MOAI or within 14 days of discontinuing either imipramine or MOAI as this may precipitate hypertensive crisis. Contraindications to imipramine also include its use with linezolid or IV methylene blue as both have MOAI properties.<xref ref-type="bibr" rid="article-23380.r5">[5]</xref></p>
      </sec>
      <sec id="article-23380.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>It is highly recommended to closely monitor patients for their clinical condition, their response to the medication, and during periods of dose adjustment. Family and caregivers should be encouraged to observe their patients and to contact their psychiatrist if needed. The therapeutic index of TCAs is narrow. Therefore, regular&#x000a0;drug monitoring is required to ensure the therapeutic blood level and, at the same time to avoid to toxic effects of imipramine.&#x000a0;</p>
        <p>Treatment with imipramine and other tricyclics usually requires a duration of around 4&#x000a0;to 5 weeks to elicit a good response. Research has shown that increasing the dose of imipramine to greater than 300ng/mL effectively treated severe depression. However, when the drug level greatly exceeds 300ng/mL, it will be more likely to be associated with significant and serious side effects.&#x000a0;Extreme precautions are necessary, especially in a patient with cardiovascular disease, including conduction defects, tachycardia, acute myocardial infarction, and hepatic impairment.&#x000a0;When coadministering imipramine with a MOAI, it can lead to fatal hypertensive crisis or seizures. When imipramine is co-ingested with SSRI, it can cause serotonin syndrome.<xref ref-type="bibr" rid="article-23380.r7">[7]</xref><xref ref-type="bibr" rid="article-23380.r5">[5]</xref></p>
      </sec>
      <sec id="article-23380.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The risk of developing toxicity from imipramine and other tricyclics is greater upon increasing the dose. An overdose of imipramine can result in serious side effects, mainly cardiac dysrhythmia, critical hypotension, convulsions, coma, confusion, hyperactive reflexes, and hypothermia. Imipramine has type 1 antiarrhythmic effects as it blocks the fast sodium channel on the myocardium. Therefore, this will lead to inhibition of depolarization of the heart action potential, which will result in QRS prolongation, which can lead to cardiac arrhythmia.</p>
        <p>Acute&#x000a0;management must begin with an assessment of airway, breathing, and circulation in addition to ECG monitoring and vital signs. The initial management should primarily focus on the correction of hypoxia and acidosis if present. Treatment with sodium bicarbonate will reverse the fast sodium channel function on the myocardium, which will reverse the cardiotoxicity and will also help in increasing the pH, which can enhance the excretion of TCAs. Therefore, continuous monitoring of imipramine is important to prevent cardiotoxicity and to prevent morbidity and mortality.&#x000a0;If patients develop seizures, the recommendation is to use benzodiazepines as first-line therapy. However, dose adjustment is necessary for certain medical conditions as hepatic or renal impairment.<xref ref-type="bibr" rid="article-23380.r9">[9]</xref><xref ref-type="bibr" rid="article-23380.r10">[10]</xref><xref ref-type="bibr" rid="article-23380.r11">[11]</xref></p>
      </sec>
      <sec id="article-23380.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients should receive education about the possible side effects profile associated with imipramine and other tricyclics.; this will help patients make better decisions that fit their health. Before initiating imipramine, it is imperative to discuss with the patient&#x000a0;regarding&#x000a0;its clinical use and side effects of imipramine and other tricyclic antidepressants. Patient education about warning signs and symptoms that warrant a visit to the emergency department, such as suicidal thoughts, confusion, dizziness, severe palpitations, and vision changes, is vital before initiating therapy as well. Additionally, imipramine should be prescribed within the therapeutic dose with gradual titration as it can&#x000a0;be fatal in overdose and require close monitoring. Special precautions merit consideration for anyone on this medication. Parents should be urged to keep the drug in a locked cabinet away from the reach of children.<xref ref-type="bibr" rid="article-23380.r10">[10]</xref>&#x000a0;</p>
        <p>Managing imipramine therapy requires the efforts of an interprofessional team that includes clinicians, specialists, mid-level practitioners, pharmacists, and psychology professionals, all collaborating and communicating as a cohesive unit and engaging the patient in their own care. Psychoeducation and good interprofessional communication skills between mental and other health providers and patients are of paramount importance for a better outcome. [Level 5]</p>
      </sec>
      <sec id="article-23380.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23380&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23380">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23380/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23380">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23380.s11">
        <title>References</title>
        <ref id="article-23380.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hearn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wiffen</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Imipramine for neuropathic pain in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>May</month>
            <day>19</day>
            <volume>2014</volume>
            <issue>5</issue>
            <fpage>CD010769</fpage>
            <pub-id pub-id-type="pmid">24838845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23380.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caldwell</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Sureshkumar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic and related drugs for nocturnal enuresis in children.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Jan</month>
            <day>20</day>
            <volume>2016</volume>
            <issue>1</issue>
            <fpage>CD002117</fpage>
            <pub-id pub-id-type="pmid">26789925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23380.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dean</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Imipramine Therapy and <italic>CYP2D6</italic> and <italic>CYP2C19</italic> Genotype</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Pratt</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esquivel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kattman</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Malheiro</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <source>Medical Genetics Summaries [Internet]</source>
            <publisher-name>National Center for Biotechnology Information (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>3</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">28520379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23380.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giwa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oey</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The return of an old nemesis: Survival after severe tricyclic antidepressant toxicity, a case report.</article-title>
            <source>Toxicol Rep</source>
            <year>2018</year>
            <volume>5</volume>
            <fpage>357</fpage>
            <page-range>357-362</page-range>
            <pub-id pub-id-type="pmid">29854605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23380.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <chapter-title>Desipramine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>1</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">31643558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23380.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Opoka</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kryczyk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krakowska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Piotrowska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gdula-Argasi&#x00144;ska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ka&#x00142;a</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Linek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muszy&#x00144;ska</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The evaluation of effect of selected metal ions on the efficiency of passive and active transport of imipramine.</article-title>
            <source>Psychiatr Pol</source>
            <year>2019</year>
            <month>Oct</month>
            <day>30</day>
            <volume>53</volume>
            <issue>5</issue>
            <fpage>1169</fpage>
            <page-range>1169-1179</page-range>
            <pub-id pub-id-type="pmid">31955193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23380.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <chapter-title>Antidepressant Agents</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>4</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">31643899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23380.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <chapter-title>Imipramine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>4</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">31643220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23380.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dokken</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Fairley</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Sodium Channel Blocker Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">30521265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23380.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Khalid</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Waseem</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Tricyclic Antidepressant Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">28613681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23380.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000fc;loglu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Orak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ust&#x000fc;ndag</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altunci</surname>
                <given-names>YA</given-names>
              </name>
            </person-group>
            <article-title>Analysis of amitriptyline overdose in emergency medicine.</article-title>
            <source>Emerg Med J</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>296</fpage>
            <page-range>296-9</page-range>
            <pub-id pub-id-type="pmid">20923818</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
